Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
127 hedge funds and large institutions have $1.06B invested in Alder Biopharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 25 reducing their positions, and 13 closing their positions.
116% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 25
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
3% more funds holding
Funds holding: 123 → 127 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less call options, than puts
Call options by funds: $1.15M | Put options by funds: $1.16M
12% less capital invested
Capital invested by funds: $1.21B → $1.06B (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$34.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$20M |
| 3 |
BlackRock
New York
|
+$14.2M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$8.99M |
| 5 |
Goldman Sachs
New York
|
+$6.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$31.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.1M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.8M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.43M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.46M |
ALDR Hedge Fund Activity: Q2 2019 in Review
127 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2019, worth a combined $1.06B — down 12% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ALDR positions and 13 closed out — a net gain of 7 holders — while 54 added to existing stakes and 25 trimmed.
The largest buyer was Bellevue Group, adding an estimated $34.3M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $31.5M sold.
- 127 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2019, up from 123 in Q1 2019.
- Funds reported $1.06B of Alder Biopharmaceuticals stock for Q2 2019, down 12% quarter-over-quarter.
- 20 funds opened new Alder Biopharmaceuticals positions in Q2 2019 and 13 closed out, a net change of +7 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $34.3M added.
- The largest Alder Biopharmaceuticals seller in Q2 2019 was PFM Health Sciences, an estimated $31.5M sold.
Based on aggregated 13F filings for Q2 2019.